Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

Homi-lung · Long-term alterations of host-microbiome interactions and cardiovascular and respiratory diseases progression after pneumonia

HORIZONStatus: SIGNED1 January 202431 December 2028EU funding €6,999,983Call HORIZON-HLTH-2023-DISEASE-03

Challenges. The incidence of cardiovascular diseases (CVD) increases after infections, but causal mechanisms are not understood yet. Pneumonia, which can be acquired in the community (such as flu and COVID-19) or during hospitalization, is a leading cause of infectious diseases. The main idea of the Homi-lung project is to investigate the causal relationship between CVD progression and the immune and microbiome alterations observed after pneumonia. Objectives. During the Homi-lung project, we aim to i) define the medical and societal, and patient needs; ii) increase medical doctor’s knowledge of the physiological processes linking pneumonia and CVD; iii) enable early identification of patients at risk of CVD progression; and iv) preclinically develop new treatments.Implementation. The Homi-lung project will address this challenge by comparing CVD rates between patients cured of pneumonia and matched patients who had not developed pneumonia during a prospective 3-year follow-up. We will analyze longitudinal samples collected in these populations and develop new algorithms by artificial intelligence to associate host-microbiome interactions with CVD progression. We will also demonstrate the causal link between CVD progression and host-microbiome interactions in preclinical pneumonia models. The interdisciplinary and ambitious Homi-lung project brings together 8 partners from 5 EU countries, with expertise in pneumonia, CVD, immunology, microbiome, and artificial intelligence and is uniquely placed to reach these objectives.Impacts. The project will provide clinicians with robust evidence contributing to identifying patients at risk of CVD after pneumonia. By developing new biomarkers and preclinical validating treatments to TRL4, the project will contribute to improving patients’ recovery and reducing the burden of infections. This project, particularly timely after the COVID-19 pandemic crisis, will also increase European preparedness for the next pandemic.

Consortium · 11 organisations

coordinator

NANTES UNIVERSITE

FR · €1,848,126

thirdParty

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR

participant

BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE

FR · €723,999

participant

REGENTS OF THE UNIVERSITY OF MICHIGAN

US · €549,909

thirdParty

ECOLE CENTRALE DE NANTES

FR

participant

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM

NL · €815,937

participant

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

ES · €619,875

participant

TEL AVIV UNIVERSITY

IL · €631,250

participant

ELLINIKO INSTITUTO MELETIS TIS SIPSIS

EL · €896,875

thirdParty

HOSPITAL CLINIC DE BARCELONA

ES

participant

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

FR · €914,013

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.